PDC and peripheral arterial disease: While oral PHD inhibitors like Roxadustat, Daprodustat, and Vadadustat have been approved to stimulate erythropoiesis in chronic kidney disease, their efficacy in promoting angiogenesis for PAD or CLTI remains unproven.